Full-Time

Oncology Specialist

Confirmed live in the last 24 hours

BillionToOne

BillionToOne

201-500 employees

Molecular diagnostics for prenatal and oncology testing

Biotechnology
Healthcare

Compensation Overview

$137.7k - $163.2kAnnually

+ Equity Options + Bonus + Uncapped Commission

Senior, Expert

Pennsylvania, USA

Field-based position in Pennsylvania; remote work is allowed but requires presence in the state.

Category
Field Sales
Sales & Account Management
Required Skills
Sales

You match the following BillionToOne's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor's Degree or equivalent experience
  • Experience selling diagnostic testing in the oncology field and maintaining a strong network of relationships with oncologists; demonstrated successful sales track record (e.g., award winner - President Club, Chairman Club, Rookie of the Year or equivalent) or experience as a Physicians Assistant (PA), Nurse Practitioner (NP) or Registered Nurse (RN) ordering late stage cancer liquid biopsy tests
  • Understanding of buyer/decision maker types, listening, presentation skills, and ability to assess and respond to customer needs
  • Lives within the defined territory and centrally located to defined accounts
  • Commitment to travel within defined territory
  • Excellent organizational and communication skills (written and verbal) with demonstrated ability to effectively present to both internal and external customers
  • Effective time management skills required with a demonstrated ability to assess and prioritize opportunity required
  • Exceptionally bright, flexible, self-motivated and results oriented with strong interpersonal and analytical skills and the ability to think strategically as well as execute tactically
  • Must act with a sense of urgency, with a focus on closing business
  • Ability to assess the needs of medical professionals and staff members with a focus on consultative sales, coordination of logistics, and problem solving
  • Strong desire to work in a startup environment and must work independently with an internal drive to be successful
Responsibilities
  • Increasing revenue and driving market development through direct sales to individual Oncologists
  • Creating and implementing a strategic business plan to grow revenue quickly in your geography
  • Sales efforts include effective prospecting and cultivating new business and maintaining key relationships

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne's business model centers on providing these diagnostic services directly to healthcare providers, generating revenue through the sale of testing services that inform treatment decisions. The goal of BillionToOne is to enhance the accuracy, efficiency, and accessibility of molecular testing, driven by a commitment to growth, equality, and teamwork in making a positive impact on healthcare.

Company Size

201-500

Company Stage

Series D

Total Funding

$380.2M

Headquarters

Menlo Park, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • BillionToOne achieved over 100% revenue growth, reaching $153 million in 2024.
  • The company secured a billion-dollar valuation with a $130 million funding round.
  • Expansion in Austin, Texas, will create 1,000 jobs and increase production capacity.

What critics are saying

  • Emerging startups in molecular diagnostics could erode BillionToOne's market share.
  • Rapid technological advancements require continuous innovation to maintain competitiveness.
  • Economic instability in target markets may affect product affordability and adoption.

What makes BillionToOne unique

  • BillionToOne's QCT technology detects DNA variations at single base-pair resolution.
  • Their non-invasive prenatal tests replace risky procedures like amniocentesis.
  • Northstar products offer precise therapy selection and monitoring for oncology patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

2%
PR Newswire
Jan 28th, 2025
Billiontoone Reports Over 100% Growth In Revenue Year-Over-Year

Company Announces Record Financial Results at 43rd Annual J.P. Morgan Healthcare ConferenceMENLO PARK, Calif., Jan. 28, 2025 /PRNewswire/ -- BillionToOne , a next-generation molecular diagnostics company, announced record financial results at this year's J.P. Morgan Healthcare Conference in San Francisco. In 2024, the company's revenue reached $153 million, more than doubling from $72 million in 2023.BillionToOne's success has been driven primarily by its prenatal testing business, which has captured an estimated 15% market share in the U.S."We saw strong momentum in our prenatal business during 2024, with tremendous revenue growth and profitability in the fourth quarter," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne

Webrazzi
Dec 30th, 2024
2024 Yılında En Çok Yatırım Alan 10 Yerli Girişim

2021, 2022 ve 2023 yıllarında en yüksek yatırım alan yerli girişimleri sizlere aktarmıştık. Bir yılın daha sonuna gelirken, 2024 yılında en yüksek yatırımları alan yerli girişimleri derledik. Geçtiğimiz yılın en çok yatırım alan 10 yerli girişimiyle kıyaslandığında bu yıl yatırım miktarlarının yükseldiği görülmekte. Aslında 2022 yılından 2023 yılına gelindiğinde yatırım miktarlarında bir düşüş ile karşılaşılmıştı. Bu durumun 2024 yılında değiştiğini söylemek mümkün. Geçen yıl 105 milyon dolar ile listedeki en yüksek yatırımı alan Insider, bu yıl aldığı 500 milyon dolar ile çıtayı yükseltirken zirvedeki yerini korudu

PR Newswire
Dec 23rd, 2024
Billiontoone To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Dec. 23, 2024 /PRNewswire/ -- BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that they will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 14, 2025.BillionToOne marks a transformative year of achievements as it looks toward 2025. The company closed an oversubscribed, upsized Series D funding round led by Premji Invest in June, and was recently recognized as the Biotech Breakthrough Awards' Diagnostics Company of the Year. More than 500,000 patients have received BillionToOne tests to date, and the company has grown from $0M to $150M+ in annual recurring revenue over the past five years.This will be BillionToOne's second year in attendance at the J.P. Morgan Healthcare Conference, and the company will present on the topic of "Redefining Molecular Diagnostics with Single-Molecule Precision." Presentation details are as follows:Location: Mission Bay (32nd Floor) at The WestinDate: Tuesday, January 14, 2025Time: 2:30-2:55 pm PTA webcast and presentation materials will be available on BillionToOne's website: https://billiontoone.com/event/jpm-2025-43rd-annual-healthcare-conference/About BillionToOneHeadquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for everyone

BillionToOne
Nov 20th, 2024
BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards

BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards.

LabPulse
Sep 12th, 2024
BillionToOne to open new facility in Austin, Texas

Molecular diagnostics firm BillionToOne broke ground Wednesday on a 220,000-sq-ft facility in Austin, TX, that is expected to bring 1,000 jobs to the city.